Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline updateJulia Bohlius, Alejandro Lazo‐Langner, Kari Bohlke et al.|Blood Advances|2019Cited by 165
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline UpdateJulia Bohlius, Alejandro Lazo‐Langner, Kari Bohlke et al.|Journal of Clinical Oncology|2019Cited by 152
Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trialMichael J. Kovacs, Marc Rodger, Philip S. Wells et al.|BMJ|2021Cited by 105
Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)Michael J. Kovacs, David Anderson, Marc Rodger et al.|Blood|2018Cited by 9
Clinical characteristics, multiorgan dysfunction and outcomes of patients with COVID-19: a prospective case seriesKimia Honarmand, John Basmaji, Kyle Fiorini et al.|CMAJ Open|2022Cited by 4